ArticleBMC complementary and alternative medicine2010
Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes.
Article in BMC complementary and alternative medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 96 citations in OpenAlex.
- Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients.Nutrition journal · 2015Trial
- Multidimensional Uses of Bitter Melon (Current organic synthesis · 2025Review
- Review
- Inhibition of Differentiation of 3T3-L1 Cells by Increasing Glioma-Associated Oncogene Expression inPreventive nutrition and food science · 2024Article
- Saponins fromFood science & nutrition · 2023Article
- Review
- The Anti-Obesity Effects of Lemon Fermented Products in 3T3-L1 Preadipocytes and in a Rat Model with High-Calorie Diet-Induced Obesity.Nutrients · 2021Article
- Anti-Obesity and Lipid Metabolism Effects ofJournal of microbiology and biotechnology · 2021Article
- Uteroplacental Insufficiency with Hypoxia Upregulates Placental PPARγ-KMT5A Axis in the Rat.Reproductive sciences (Thousand Oaks, Calif.) · 2021Article
- Three Selected Edible Crops of the GenusFrontiers in pharmacology · 2021Review
- Exploring the inhibitory potentials ofIn silico pharmacology · 2021Article
- Vanadium-protein complex inhibits human adipocyte differentiation through the activation of β-catenin and LKB1/AMPK signaling pathway.PloS one · 2020Article
- The Role ofInternational journal of environmental research and public health · 2019Review
- Article
- Fifty Percent Ethanolic Extract ofReports of biochemistry & molecular biology · 2017Article
- Effects of Karela (Bitter Melon; Momordica charantia) on genes of lipids and carbohydrates metabolism in experimental hypercholesterolemia: biochemical, molecular and histopathological study.BMC complementary and alternative medicine · 2017Article
- Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.Integrative cancer therapies · 2016Article
- Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome.Journal of lipids · 2015Review
- Therapeutic phytogenic compounds for obesity and diabetes.International journal of molecular sciences · 2014Review
- Plant natural products as an anti-lipid droplets accumulation agent.Journal of natural medicines · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundEscalating trends of obesity and associated type 2 diabetes (T2D) has prompted an increase in the use of alternative and complementary functional foods. Momordica charantia or bitter melon (BM) that is traditionally used to treat diabetes and complications has been demonstrated to alleviate hyperglycemia as well as reduce adiposity in rodents. However, its effects on human adipocytes remain unknown. The objective of our study was to investigate the effects of BM juice (BMJ) on lipid accumulation and adipocyte differentiation transcription factors in primary human differentiating preadipocytes and adipocytes.
methodsCommercially available cryopreserved primary human preadipocytes were treated with and without BMJ during and after differentiation. Cytotoxicity, lipid accumulation, and adipogenic genes mRNA expression was measured by commercial enzymatic assay kits and semi-quantitative RT-PCR (RT-PCR).
resultsPreadipocytes treated with varying concentrations of BMJ during differentiation demonstrated significant reduction in lipid content with a concomitant reduction in mRNA expression of adipocyte transcription factors such as, peroxisome proliferator-associated receptor gamma (PPARgamma) and sterol regulatory element-binding protein 1c (SREBP-1c) and adipocytokine, resistin. Similarly, adipocytes treated with BMJ for 48 h demonstrated reduced lipid content, perilipin mRNA expression, and increased lipolysis as measured by the release of glycerol.
conclusionOur data suggests that BMJ is a potent inhibitor of lipogenesis and stimulator of lipolysis activity in human adipocytes. BMJ may therefore prove to be an effective complementary or alternative therapy to reduce adipogenesis in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.